- Trial phase
- Phase 2 (registrational-intent in PCNSL)
- Time to market
- Uncertain; the registrational PCNSL study is still enrolling with full enrollment targeted within 12-18 months from March 2026. If data are positive and an NDA follows, potential approval would be at least 2-3 years out, assuming sufficient capital to complete the trials.
- Why 4/10
- No specific hard, dated catalyst (PDUFA, pivotal topline readout, or AdComm) is scheduled within the next ~12 months. The registrational TakeAim Lymphoma study in PCNSL is still enrolling; management targeted full enrollment within 12-18 months from March 2026, pushing any readout to late 2027 at earliest. Emavusertib is Curis's only clinical asset and the company's entire value depends on it, but without a dated binary event the maximum impact score is 4 per the rubric.
The next major catalyst is a topline data readout from the registrational TakeAim Lymphoma study in PCNSL, which management targeted to fully enroll within 12-18 months from March 2026 (so late 2027 at the earliest). No specific readout date has been announced. In the near term, watch for the shareholder vote on the proposed reverse stock split, which the company needs to maintain Nasdaq listing, and for any further financing rounds given the cash burn (Q3 2026 net loss of $8.12M).
Price Chart
Executive Summary
Emavusertib (CA-4948) is Curis, Inc.'s only clinical-stage asset, an orally available small-molecule IRAK4 and FLT3 inhibitor being evaluated in several blood-cancer trials. The most advanced program is the registrational TakeAim Lymphoma Phase 1/2 study in relapsed/refractory primary CNS lymphoma (PCNSL). Updated data from July 2026 showed an 86% objective response rate in BTK-inhibitor-naive PCNSL patients (6/7) and 26% in BTK-inhibitor-experienced patients (10/39). A separate Phase 2 TakeAim CLL study combining emavusertib with zanubrutinib is enrolling. While the PCNSL data look encouraging, Curis faces severe financial strain: the stock trades near $0.44, it received a Nasdaq delisting notice on November 2, 2026 for failing the $1 minimum bid price, and it has raised capital through dilutive offerings ($8.5M private placement in October 2026, $5.6M public offering in August 2026).
How It Works
Emavusertib is a pill that blocks two enzymes called IRAK4 and FLT3, which are overactive in certain blood cancers. By inhibiting these targets, the drug aims to disrupt signaling pathways that help cancer cells survive and multiply. It is being tested alone and in combination with other drugs for several types of lymphoma, leukemia, and myelodysplastic syndromes.
Trial Status
The TakeAim Lymphoma Phase 1/2 study in relapsed/refractory PCNSL is described as registrational (designed to support FDA approval). Updated July 2026 data showed an 86% objective response rate in BTK-inhibitor-naive patients. The TakeAim CLL Phase 2 study combining emavusertib with zanubrutinib in chronic lymphocytic leukemia began enrolling in mid-2026 with 11 clinical sites opened and the first six patients consented by July 2026. A frontline AML triplet study (emavusertib + azacitidine + venetoclax) presented data at ASH in December 2025.
The Two-Sided Case
Upcoming Catalysts
- Shareholder vote on proposed reverse stock split (needed to address Nasdaq bid-price deficiency)
- Additional enrollment updates for TakeAim Lymphoma registrational study in PCNSL
- Potential data updates from TakeAim CLL Phase 2 combination study with zanubrutinib
- Any further equity financings given cash burn (Q3 2026 net loss of $8.12M)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Curis, Inc. PRESS-RELEASE CRIS ·Originating report